203 related articles for article (PubMed ID: 19234609)
1. Integrative analysis of epigenetic modulation in melanoma cell response to decitabine: clinical implications.
Halaban R; Krauthammer M; Pelizzola M; Cheng E; Kovacs D; Sznol M; Ariyan S; Narayan D; Bacchiocchi A; Molinaro A; Kluger Y; Deng M; Tran N; Zhang W; Picardo M; Enghild JJ
PLoS One; 2009; 4(2):e4563. PubMed ID: 19234609
[TBL] [Abstract][Full Text] [Related]
2. Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.
Budden T; van der Westhuizen A; Bowden NA
BMC Cancer; 2018 Jan; 18(1):100. PubMed ID: 29373959
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic regulation by decitabine of melanoma differentiation in vitro and in vivo.
Alcazar O; Achberger S; Aldrich W; Hu Z; Negrotto S; Saunthararajah Y; Triozzi P
Int J Cancer; 2012 Jul; 131(1):18-29. PubMed ID: 21796622
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide methylation and expression profiling identifies promoter characteristics affecting demethylation-induced gene up-regulation in melanoma.
Rubinstein JC; Tran N; Ma S; Halaban R; Krauthammer M
BMC Med Genomics; 2010 Feb; 3():4. PubMed ID: 20144234
[TBL] [Abstract][Full Text] [Related]
5. Use of integrative epigenetic and cytogenetic analyses to identify novel tumor-suppressor genes in malignant melanoma.
Mithani SK; Smith IM; Califano JA
Melanoma Res; 2011 Aug; 21(4):298-307. PubMed ID: 21606880
[TBL] [Abstract][Full Text] [Related]
6. The depletion of DNA methyltransferase-1 and the epigenetic effects of 5-aza-2'deoxycytidine (decitabine) are differentially regulated by cell cycle progression.
Al-Salihi M; Yu M; Burnett DM; Alexander A; Samlowski WE; Fitzpatrick FA
Epigenetics; 2011 Aug; 6(8):1021-8. PubMed ID: 21725200
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
8. Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo.
Steele N; Finn P; Brown R; Plumb JA
Br J Cancer; 2009 Mar; 100(5):758-63. PubMed ID: 19259094
[TBL] [Abstract][Full Text] [Related]
9. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells.
Shin DY; Sung Kang H; Kim GY; Kim WJ; Yoo YH; Choi YH
Biomed Pharmacother; 2013 May; 67(4):305-11. PubMed ID: 23582784
[TBL] [Abstract][Full Text] [Related]
10. DSS1 promoter hypomethylation and overexpression predict poor prognosis in melanoma and squamous cell carcinoma patients.
Venza M; Visalli M; Catalano T; Beninati C; Teti D; Venza I
Hum Pathol; 2017 Feb; 60():137-146. PubMed ID: 27825810
[TBL] [Abstract][Full Text] [Related]
11. Decitabine induces G2/M cell cycle arrest by suppressing p38/NF-κB signaling in human renal clear cell carcinoma.
Shang D; Han T; Xu X; Liu Y
Int J Clin Exp Pathol; 2015; 8(9):11140-8. PubMed ID: 26617834
[TBL] [Abstract][Full Text] [Related]
12. Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
Tang Z; Liu L; Borlak J
Clin Epigenetics; 2023 May; 15(1):89. PubMed ID: 37208732
[TBL] [Abstract][Full Text] [Related]
13. Decitabine up-regulates S100A2 expression and synergizes with IFN-gamma to kill uveal melanoma cells.
Gollob JA; Sciambi CJ
Clin Cancer Res; 2007 Sep; 13(17):5219-25. PubMed ID: 17785578
[TBL] [Abstract][Full Text] [Related]
14. Decitabine, independent of apoptosis, exerts its cytotoxic effects on cell growth in melanoma cells.
Liu QY; Chen DW; Xie LP; Zhang RQ; Wang HZ
Environ Toxicol Pharmacol; 2011 Nov; 32(3):423-9. PubMed ID: 22004962
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
[TBL] [Abstract][Full Text] [Related]
16. Integrative genomic analysis of temozolomide resistance in diffuse large B-cell lymphoma.
Leshchenko VV; Kuo PY; Jiang Z; Thirukonda VK; Parekh S
Clin Cancer Res; 2014 Jan; 20(2):382-92. PubMed ID: 24178621
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells.
Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W
J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694
[TBL] [Abstract][Full Text] [Related]
18. Will DNA methylation inhibitors work in solid tumors? A review of the clinical experience with azacitidine and decitabine in solid tumors.
Cowan LA; Talwar S; Yang AS
Epigenomics; 2010 Feb; 2(1):71-86. PubMed ID: 22122748
[TBL] [Abstract][Full Text] [Related]
19. Pathway landscapes and epigenetic regulation in breast cancer and melanoma cell lines.
El Baroudi M; La Sala D; Cinti C; Capobianco E
Theor Biol Med Model; 2014 May; 11 Suppl 1(Suppl 1):S8. PubMed ID: 25077705
[TBL] [Abstract][Full Text] [Related]
20. Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy.
Takeshima H; Wakabayashi M; Hattori N; Yamashita S; Ushijima T
Carcinogenesis; 2015 Feb; 36(2):192-201. PubMed ID: 25477340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
